During its earnings call this week, the liquid biopsy firm said it is planning a 10,000-patient trial to test its Lunar assay for colorectal cancer screening.
The British molecular diagnostics firm recently completely a redesign of its point-of-care system, called Q-POC, and is planning to seek a CE-IVD mark for the device later this year.
The BioFire FilmArray Pneumonia panel will be used to optimize clinical trial enrollment for an antibiotic to treat combat carbapenem-resistant A. baumannii infections.
Following promising data from its Circulating Cell-free Genome Atlas study, the firm decided to pivot its breast cancer trial to support its multi-cancer test.
The company is developing a new gold standard comparator test after it encountered problems with typical culture methods it used in developing a new pneumonia assay.
Developers claim the immunochromatographic assay has advantages over other tests on the market for diagnosing TB in HIV patients, as well as the conventional approach.
The firm said that its system is expected to deliver up to 50 AST tests per day and match the daily production of the highest-throughput systems in the market.
